Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 hsCAR-T for Refractory/Relapsed B-ALL
NCT03902197Phase 2Unknown
- Sponsor
- Xuanwu Hospital
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of CD19hs CAR-T in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Xuanwu Hospital. Status: unknown.
02
Drugs
CD19hs CAR-T
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03902197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03902197.